A detailed history of Jennison Associates LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Jennison Associates LLC holds 11,663,497 shares of ARQT stock, worth $110 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
11,663,497
Previous 11,571,694 0.79%
Holding current value
$110 Million
Previous $108 Million 0.79%
% of portfolio
0.07%
Previous 0.07%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$8.32 - $11.0 $763,800 - $1.01 Million
91,803 Added 0.79%
11,663,497 $108 Million
Q2 2024

Aug 05, 2024

SELL
$7.24 - $12.53 $4.38 Million - $7.58 Million
-604,621 Reduced 4.97%
11,571,694 $108 Million
Q1 2024

May 02, 2024

BUY
$3.25 - $11.77 $10.1 Million - $36.6 Million
3,110,233 Added 34.31%
12,176,315 $121 Million
Q4 2023

Feb 01, 2024

BUY
$1.84 - $4.82 $8.53 Million - $22.3 Million
4,633,907 Added 104.55%
9,066,082 $29.3 Million
Q3 2023

Oct 31, 2023

BUY
$5.31 - $10.98 $733,889 - $1.52 Million
138,209 Added 3.22%
4,432,175 $23.5 Million
Q2 2023

Aug 03, 2023

BUY
$7.51 - $15.0 $15.6 Million - $31.2 Million
2,079,476 Added 93.9%
4,293,966 $40.9 Million
Q1 2023

Apr 26, 2023

BUY
$10.23 - $17.14 $8.35 Million - $14 Million
816,211 Added 58.37%
2,214,490 $24.4 Million
Q4 2022

Feb 09, 2023

BUY
$13.96 - $20.4 $120,935 - $176,725
8,663 Added 0.62%
1,398,279 $20.7 Million
Q3 2022

Nov 01, 2022

BUY
$17.85 - $26.95 $17 Million - $25.7 Million
954,597 Added 219.44%
1,389,616 $26.6 Million
Q2 2022

Aug 02, 2022

BUY
$16.33 - $22.2 $7.1 Million - $9.66 Million
435,019 New
435,019 $9.27 Million

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $568M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track This Portfolio

Track Jennison Associates LLC Portfolio

Follow Jennison Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.